Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-inducing peptides - FunPep/Osaka University School of Medicine

Next Previous
Drug Profile

Research programme: antibody-inducing peptides - FunPep/Osaka University School of Medicine

Alternative Names: antibody-derived peptides

Latest Information Update: 22 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FunPep; Osaka University School of Medicine
  • Developer FunPep; Kagawa University; Kyoto Prefectural University of Medicine; MEDIPAL HOLDINGS CORPORATION; Osaka University School of Medicine; Shionogi; Sumitomo Pharma
  • Class Analgesics; Antiallergics; Antihypertensives; Antineoplastics; Antithrombotics; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypersensitivity
  • Research Familial adenomatous polyposis; Hypertension; Neurological disorders; Pain; Psoriasis; Thrombosis

Most Recent Events

  • 22 Sep 2026 Preclinical development is ongoing in Japan (Funpep pipeline September 2026)
  • 22 Sep 2026 Funpep and Tokyo University enters into a joint research agreement on antibody-derived peptides for Heart failure (Funpep pipeline September 2026)
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Allergy in Japan (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top